Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to two new employees as part of their inducement package. The grants, approved on March 23, 2025, by the compensation committee, allow the purchase of a total of 30,000 shares of common stock.
The stock options will vest quarterly over a four-year period, with 1/16 of the shares vesting each quarter, contingent on continued employment. These awards were issued under Biomea's 2023 Inducement Equity Plan, which was adopted by the board on November 17, 2023, and comply with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants for new employees.
Biomea Fusion (Nasdaq: BMEA), una società nel settore delle medicine per il diabete e l'obesità in fase clinica, ha concesso opzioni su azioni a due nuovi dipendenti come parte del loro pacchetto di incentivazione. Le concessioni, approvate il 23 marzo 2025 dal comitato per la compensazione, consentono l'acquisto di un totale di 30.000 azioni ordinarie.
Le opzioni su azioni matureranno trimestralmente nell'arco di un periodo di quattro anni, con 1/16 delle azioni che maturano ogni trimestre, a condizione di un impiego continuativo. Questi premi sono stati emessi nell'ambito del Piano di Equità per Incentivi 2023 di Biomea, adottato dal consiglio il 17 novembre 2023, e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) relativa alle concessioni di incentivazione per i nuovi dipendenti.
Biomea Fusion (Nasdaq: BMEA), una empresa en etapa clínica dedicada a medicamentos para la diabetes y la obesidad, ha otorgado opciones sobre acciones a dos nuevos empleados como parte de su paquete de incentivos. Las concesiones, aprobadas el 23 de marzo de 2025 por el comité de compensación, permiten la compra de un total de 30,000 acciones ordinarias.
Las opciones sobre acciones se adquirirán trimestralmente durante un período de cuatro años, con 1/16 de las acciones adquiriéndose cada trimestre, condicionado a la continuidad del empleo. Estos premios se emitieron bajo el Plan de Equidad para Incentivos 2023 de Biomea, que fue adoptado por la junta el 17 de noviembre de 2023, y cumplen con la Regla de Cotización Nasdaq 5635(c)(4) sobre concesiones de incentivos para nuevos empleados.
Biomea Fusion (Nasdaq: BMEA), 당뇨병 및 비만 치료제를 개발 중인 임상 단계 회사가 두 명의 신규 직원에게 유인 패키지의 일환으로 스톡 옵션을 부여했습니다. 이 부여는 2025년 3월 23일 보상 위원회에서 승인되었으며, 총 30,000주의 보통주를 구매할 수 있는 권한을 제공합니다.
스톡 옵션은 4년 동안 분기별로 발생하며, 매 분기마다 1/16의 주식이 발생하며, 지속적인 고용을 조건으로 합니다. 이 보상은 Biomea의 2023 유인 주식 계획에 따라 발행되었으며, 이는 2023년 11월 17일 이사회에서 채택되었고, 신규 직원에 대한 유인 부여에 관한 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Biomea Fusion (Nasdaq: BMEA), une entreprise en phase clinique spécialisée dans les médicaments pour le diabète et l'obésité, a accordé des options sur actions à deux nouveaux employés dans le cadre de leur package d'incitation. Les attributions, approuvées le 23 mars 2025 par le comité de rémunération, permettent l'achat d'un total de 30 000 actions ordinaires.
Les options sur actions seront acquises trimestriellement sur une période de quatre ans, avec 1/16 des actions acquises chaque trimestre, sous réserve d'un emploi continu. Ces récompenses ont été émises dans le cadre du Plan d'Équité d'Incentive 2023 de Biomea, qui a été adopté par le conseil d'administration le 17 novembre 2023, et sont conformes à la Règle de Cotation Nasdaq 5635(c)(4) concernant les attributions d'incitation pour les nouveaux employés.
Biomea Fusion (Nasdaq: BMEA), ein Unternehmen in der klinischen Phase für Medikamente gegen Diabetes und Fettleibigkeit, hat zwei neuen Mitarbeitern im Rahmen ihres Anreizpakets Aktienoptionen gewährt. Die Gewährungen, die am 23. März 2025 vom Vergütungsausschuss genehmigt wurden, ermöglichen den Kauf von insgesamt 30.000 Stammaktien.
Die Aktienoptionen werden vierteljährlich über einen Zeitraum von vier Jahren fällig, wobei jedes Quartal 1/16 der Aktien fällig wird, vorausgesetzt, das Arbeitsverhältnis bleibt bestehen. Diese Auszeichnungen wurden im Rahmen des Anreiz-Eigenkapitalplans 2023 von Biomea ausgegeben, der am 17. November 2023 vom Vorstand angenommen wurde, und entsprechen der Nasdaq-Listing-Regel 5635(c)(4) bezüglich Anreizgewährungen für neue Mitarbeiter.
- None.
- None.
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea’s board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee’s continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com
FAQ
How many shares were granted in Biomea Fusion's (BMEA) March 2025 inducement grants?
What is the vesting schedule for BMEA's March 2025 employee stock options?
When did Biomea Fusion (BMEA) establish its 2023 Inducement Equity Plan?
How many new employees received BMEA stock options in March 2025?
